WO2007146024A3 - Cytomegalovirus surface protein complex for use in vaccines and as a drug target - Google Patents

Cytomegalovirus surface protein complex for use in vaccines and as a drug target Download PDF

Info

Publication number
WO2007146024A3
WO2007146024A3 PCT/US2007/013365 US2007013365W WO2007146024A3 WO 2007146024 A3 WO2007146024 A3 WO 2007146024A3 US 2007013365 W US2007013365 W US 2007013365W WO 2007146024 A3 WO2007146024 A3 WO 2007146024A3
Authority
WO
WIPO (PCT)
Prior art keywords
cmv
protein complex
vaccines
methods
pul130
Prior art date
Application number
PCT/US2007/013365
Other languages
French (fr)
Other versions
WO2007146024A2 (en
Inventor
Thomas Shenk
Original Assignee
Univ Princeton
Wang Dai
Thomas Shenk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38832360&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007146024(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Princeton, Wang Dai, Thomas Shenk filed Critical Univ Princeton
Priority to EP07777421.4A priority Critical patent/EP2037959B1/en
Priority to EP16152758.5A priority patent/EP3031469B1/en
Priority to JP2009514365A priority patent/JP5822433B2/en
Priority to CA002654563A priority patent/CA2654563A1/en
Publication of WO2007146024A2 publication Critical patent/WO2007146024A2/en
Publication of WO2007146024A3 publication Critical patent/WO2007146024A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/088—Varicella-zoster virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Abstract

Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit human CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.
PCT/US2007/013365 2006-06-07 2007-06-06 Cytomegalovirus surface protein complex for use in vaccines and as a drug target WO2007146024A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP07777421.4A EP2037959B1 (en) 2006-06-07 2007-06-06 Cytomegalovirus surface protein complex for use in vaccines and as a drug target
EP16152758.5A EP3031469B1 (en) 2006-06-07 2007-06-06 Cytomegalovirus surface protein complex for use in vaccines and as a drug target
JP2009514365A JP5822433B2 (en) 2006-06-07 2007-06-06 Cytomegalovirus surface protein complex for use as a drug target in a vaccine
CA002654563A CA2654563A1 (en) 2006-06-07 2007-06-06 Cytomegalovirus surface protein complex for use in vaccines and as a drug target

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81168906P 2006-06-07 2006-06-07
US60/811,689 2006-06-07
US90254407P 2007-02-20 2007-02-20
US60/902,544 2007-02-20

Publications (2)

Publication Number Publication Date
WO2007146024A2 WO2007146024A2 (en) 2007-12-21
WO2007146024A3 true WO2007146024A3 (en) 2008-03-20

Family

ID=38832360

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/013365 WO2007146024A2 (en) 2006-06-07 2007-06-06 Cytomegalovirus surface protein complex for use in vaccines and as a drug target

Country Status (5)

Country Link
US (5) US7704510B2 (en)
EP (2) EP3031469B1 (en)
JP (3) JP5822433B2 (en)
CA (1) CA2654563A1 (en)
WO (1) WO2007146024A2 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2654563A1 (en) * 2006-06-07 2007-12-21 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) * 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
MX2009012067A (en) * 2007-05-11 2010-03-25 Vakzine Projekt Man Gmbh Composition containing hcmv particles.
US9439960B2 (en) * 2007-10-10 2016-09-13 The Trustees Of Princeton University Cytomegalovirus vaccines and methods of production
JP5544309B2 (en) * 2008-03-10 2014-07-09 セラクローン サイエンシーズ， インコーポレイテッド Compositions and methods for treatment and diagnosis of cytomegalovirus infection
SG10201608381SA (en) * 2008-07-16 2016-11-29 Inst Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
AU2013202396B2 (en) * 2008-07-16 2014-07-10 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
AU2012203417B2 (en) * 2008-07-16 2014-07-10 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
JP5475774B2 (en) * 2008-07-16 2014-04-16 インスティテュート フォー リサーチ イン バイオメディシン Human cytomegalovirus neutralizing antibody and use thereof
US8580276B2 (en) 2009-06-05 2013-11-12 City Of Hope Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
US8999398B2 (en) 2009-11-06 2015-04-07 Transtarget Inc. Polyclonal bispecific antibody compositions and method of use
BR112012015523A2 (en) 2009-12-23 2017-04-18 4-Antibody Ag human cytomegalovirus binding members, composition containing them, method of treatment, antibody molecules, production method, nucleic acid molecular, host cell, and hcmv neutralization method.
PL2590626T3 (en) 2010-07-06 2016-04-29 Glaxosmithkline Biologicals Sa Liposomes with lipids having an advantageous pka-value for rna delivery
ES2770335T3 (en) 2010-07-06 2020-07-01 Glaxosmithkline Biologicals Sa RNA administration to trigger multiple immune pathways
WO2012006369A2 (en) 2010-07-06 2012-01-12 Novartis Ag Immunisation of large mammals with low doses of rna
LT3981427T (en) 2010-08-31 2022-08-10 Glaxosmithkline Biologicals S.A. Pegylated liposomes for delivery of immunogen-encoding rna
EP2614072A4 (en) * 2010-09-09 2014-03-19 Univ Virginia Commonwealth Human cytomegalovirus vaccine
WO2012047732A2 (en) * 2010-09-29 2012-04-12 Genentech, Inc. Antibody compositions and methods of use
MX363307B (en) 2010-10-11 2019-03-20 Novartis Ag Star Antigen delivery platforms.
CA2825825A1 (en) * 2011-01-27 2012-08-02 The Trustees Of Princeton University Inhibitors of mtor kinase as anti-viral agents
CA2840989A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
TWI570240B (en) 2011-09-09 2017-02-11 默沙東公司 A conditional replicating cytomegalovirus as a vaccine for cmv
EP2766385A2 (en) * 2011-10-12 2014-08-20 Novartis AG Cmv antigens and uses thereof
US9139659B2 (en) * 2012-03-28 2015-09-22 Genentech, Inc. Idiotypic antibodies and uses thereof
SG11201408328VA (en) * 2012-07-06 2015-02-27 Novartis Ag Complexes of cytomegalovirus proteins
CN104838000B (en) 2012-07-27 2022-12-20 希望之城 MVA vaccine for delivering UL128 complex and preventing CMV infection
CN109045294A (en) * 2013-01-10 2018-12-21 思齐乐 Influenza virus immunization Immunogenic Compositions and its application
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
MX2016014660A (en) * 2014-05-08 2017-02-28 Pfizer Means and methods for treating cmv.
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
EP3048114A1 (en) 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. Human cytomegalovirus vaccine
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
JP6980780B2 (en) 2016-10-21 2021-12-15 モデルナティーエックス， インコーポレイテッド Human cytomegalovirus vaccine
CA3050914A1 (en) * 2017-01-27 2018-08-02 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine compositions of herpesvirus envelope protein combinations to induce immune response
WO2018193307A1 (en) 2017-04-19 2018-10-25 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
US11524069B2 (en) * 2017-09-13 2022-12-13 Sanofi Pasteur Human cytomegalovirus immunogenic composition
WO2019216929A1 (en) * 2018-05-11 2019-11-14 City Of Hope Mva vectors for expressing multiple cytomegalovirus (cmv) antigens and use thereof
MX2021004273A (en) 2018-10-17 2021-12-10 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes.
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
WO2020208082A1 (en) * 2019-04-09 2020-10-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating cmv related diseases
AU2021287508B2 (en) * 2020-06-09 2023-11-09 Km Biologics Co., Ltd. Fusion protein of pentamer and gB of cytomegalovirus, and vaccine containing said fusion protein
TWI810589B (en) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 Human cytomegalovirus gb polypeptide
US20230293673A1 (en) * 2020-08-06 2023-09-21 La Jolla Institute For Immunology Methods for treating and preventing cytomegalovirus infection
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
TW202345912A (en) * 2022-03-11 2023-12-01 財團法人國家衛生研究院 Composition comprising antigen and dna and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066629A2 (en) * 2001-02-21 2002-08-29 Gabriele Hahn Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates
US20040110188A1 (en) * 2002-07-16 2004-06-10 Gabriele Hahn Novel virus encoded chemokines determine the tissue tropism of human cytomegalovirus (HCMV)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267965B1 (en) * 1981-12-24 2001-07-31 Virogenetics Corporation Recombinant poxvirus—cytomegalovirus compositions and uses
CA2654563A1 (en) * 2006-06-07 2007-12-21 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
GB0700133D0 (en) * 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066629A2 (en) * 2001-02-21 2002-08-29 Gabriele Hahn Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates
US20040110188A1 (en) * 2002-07-16 2004-06-10 Gabriele Hahn Novel virus encoded chemokines determine the tissue tropism of human cytomegalovirus (HCMV)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG DAI ET AL: "Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 102, no. 50, December 2005 (2005-12-01), pages 18153 - 18158, XP002463457, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
US8173362B2 (en) 2012-05-08
US7704510B2 (en) 2010-04-27
US20110200633A1 (en) 2011-08-18
US11129891B2 (en) 2021-09-28
JP6274770B2 (en) 2018-02-07
EP3031469B1 (en) 2023-08-23
JP2013241442A (en) 2013-12-05
EP3031469A1 (en) 2016-06-15
JP2016128418A (en) 2016-07-14
US8828399B2 (en) 2014-09-09
CA2654563A1 (en) 2007-12-21
JP5822433B2 (en) 2015-11-24
US20120226023A1 (en) 2012-09-06
US20080187545A1 (en) 2008-08-07
JP2009539845A (en) 2009-11-19
EP2037959A2 (en) 2009-03-25
EP2037959B1 (en) 2016-01-27
WO2007146024A2 (en) 2007-12-21
US20190358317A1 (en) 2019-11-28
US20140370026A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
WO2007146024A3 (en) Cytomegalovirus surface protein complex for use in vaccines and as a drug target
WO2006013269A3 (en) Novel ethylene copolymers, compositions comprising same and preparation and treatment methods
WO2007109639A3 (en) Cytoblock preparation system and methods of use
DK1159405T3 (en) Viral particles released after human cytomegalovirus infection and their use as a vaccine
WO2006103562A3 (en) Endogenous retrovirus and proteins encoded by env gene as a target for cancer treatment
MX2010003713A (en) Cytomegalovirus vaccines and methods of production.
WO2012075040A3 (en) mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
WO2008133663A3 (en) Codon modified immunogenic compositions and methods of use
WO2010068862A3 (en) Zwitterionic polymers with therapeutic moieties
WO2007024941A3 (en) Polyvalent vaccine
WO2008039874A3 (en) Cancer stem cell antigen vaccines and methods
WO2007081896A3 (en) Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
WO2011133960A9 (en) Lysosomal storage disease enzyme
NO20055209D0 (en) Peptabody for cancer treatment
WO2006078284A3 (en) Methods and compositions related to antiviral therapy using algae and cyanobacteria
WO2009131730A3 (en) IMMUNOGENIC COMPOSITIONS FOR ACTIVATING γδ T CELLS
WO2008071573A3 (en) Powder formulation for valganciclovir
PT2126049E (en) Antibodies against human cytomegalovirus (hcmv)
WO2011038933A3 (en) Anti-hsv antibody
BRPI0921424A2 (en) attenuated respiratory syncytial virus, immunogenic composition, nucleic acid molecule, recombinant cell, method for producing a protective immune response in a patient, and use of an immunologically effective amount of one or more of the following: an attenuated rsv, a population of rsv attenuated and an immunogenic composition.
WO2012083302A3 (en) Compositions and methods for the treatment or prevention of human adenovirus-36 infection
WO2012003470A3 (en) Antibody formulations
WO2006029029A3 (en) Compositions for detection of latent hiv reactivation and methods of using the same
WO2008134643A3 (en) Trypanosoma antigens, vaccine compositions, and related methods
WO2010014567A3 (en) Variant hcmv pp65, ie1, and ie2 polynucleotides and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07777421

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2654563

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009514365

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2007777421

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU